Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Onconova Therapeutics, Inc. (NASDAQ: ONTX).

Full DD Report for ONTX

You must become a subscriber to view this report.


Recent News from (NASDAQ: ONTX)

Onconova Therapeutics to Present at the Rodman & Renshaw 20th Annual Global Investment Conference in New York City
NEWTOWN, Pa., Aug. 28, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that the Compan...
Source: GlobeNewswire
Date: August, 28 2018 08:30
Onconova Therapeutics Announces Plan for Expanding Rigosertib Clinical Trials for Patients with Myelodysplastic Syndromes (MDS) to South America with Pint Pharma
Pint Pharma to facilitate expansion of Phase 3 INSPIRE trial to Argentina, Chile, and Brazil in preparation for future studies of oral rigosertib NEWTOWN, Pa., Aug. 21, 2018 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused ...
Source: GlobeNewswire
Date: August, 21 2018 08:30
Onconova Therapeutics, Inc. (ONTX) CEO Ramesh Kumar on Q2 2018 Results - Earnings Call Transcript
Onconova Therapeutics, Inc. (NASDAQ:ONTX) Q2 2018 Earnings Conference Call August 14, 2018 9:00 AM ET Executives Ramesh Kumar - President and Chief Executive Officer Steven Fruchtman - President and Chief Medical Officer Mark Guerin - Chief Financial Officer Analysts Jos...
Source: SeekingAlpha
Date: August, 14 2018 12:49
Onconova Therapeutics Q2 revenues up 67%; shares up 5% premarket
Onconova Therapeutics ( ONTX +0.5% ) Q2 results : Revenues: $0.5M (+66.7%); Net Loss: ($4.5M) (-73.1%); Loss Per Share: ($0.07) (+75.9%); Quick Assets: $29.5M. More news on: Onconova Therapeutics, Healthcare stocks news, Earnings news and commentary, Stocks on the move, , Read more ...
Source: SeekingAlpha
Date: August, 14 2018 09:06

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-12-103.653.413.743.310566,781
2018-12-073.733.533.963.36222,165
2018-12-063.903.7453.96453.620946,647
2018-12-054.083.934.103.8670,407
2018-12-044.083.964.103.8669,432

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1010,49037,50727.9681Cover
2018-12-0752,66097,24054.1547Short
2018-12-0612,33024,54950.2261Short
2018-12-046,44535,13318.3446Cover
2018-12-0322,19452,73842.0835Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on ONTX.


About Onconova Therapeutics, Inc. (NASDAQ: ONTX)

Logo for Onconova Therapeutics, Inc. (NASDAQ: ONTX)

Not available

 

Contact Information

     

     

    Current Share Structure

    • Market Cap: $994,932 - 05/18/2018
    • Issue and Outstanding: 2,740,104 - 06/01/2016

     


    Recent Filings from (NASDAQ: ONTX)

    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: August, 14 2018
    Quarterly report with a continuing view of a company's financial position
    Filing Type: 10-QFiling Source: edgar
    Filing Date: August, 14 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: July, 30 2018
    Amendment to a SC 13D filing
    Filing Type: SC 13D/AFiling Source: edgar
    Filing Date: July, 27 2018
    Securities offered to employees under employee benefit plans
    Filing Type: S-8Filing Source: edgar
    Filing Date: July, 16 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: June, 29 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: June, 21 2018
    Report of unscheduled material events or corporate changes.
    Filing Type: 8-KFiling Source: edgar
    Filing Date: June, 08 2018
    Official notification to shareholders of matters to be brought to a vote (Proxy)
    Filing Type: DEF 14AFiling Source: edgar
    Filing Date: June, 08 2018
    Official notice of an offering of securities that is made without registration under the Securities Act in reliance on an exemption provided by Regulation D and Section 4(6) under the Act
    Filing Type: DFiling Source: edgar
    Filing Date: June, 08 2018

     

     


    Daily Technical Chart for (NASDAQ: ONTX)

    Daily Technical Chart for (NASDAQ: ONTX)


    Stay tuned for daily updates and more on (NASDAQ: ONTX)

    It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

    More to come on (NASDAQ: ONTX)

    Do your DD and if you choose, be ready to go!


     

    The Research: All source information contained in this email is from the public sources mentioned below.

     

     
     

    Thank you

    DD Report
    @DDReports

     

     


    Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in ONTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of ONTX and does not buy, sell, or trade any shares of ONTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/